BiotechTube
Restem

Restem

San Diego, United States· Est.
restem.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Restem is a clinical-stage biotech advancing a dual-platform approach in cell therapy. Its lead platform, Restem-L, utilizes Umbilical Cord Lining Modified Progenitor Cells (UMPCs) for autoimmune disorders and is preparing for Phase 2/3 trials in Idiopathic Inflammatory Myopathy with FDA Fast Track and Orphan Drug designations. The company also has an activated Natural Killer (aNK) cell program targeting cellular senescence in age-related diseases and possesses end-to-end manufacturing capabilities.

Autoimmune DisordersNeurological DisordersAge-related Diseases

Technology Platform

Proprietary platforms leveraging Umbilical Cord Lining Modified Progenitor Cells (UMPCs) for immunomodulation and tissue repair, and Activated Natural Killer (aNK) Cells for targeting cellular senescence.

Opportunities

The global autoimmune disease market is large and growing, with a high unmet need for safer, targeted therapies beyond immunosuppressants.
Restem's off-the-shelf, scalable cell therapy platform and its Orphan Drug designations provide a pathway to address niche markets with favorable economics before expanding into larger indications like Rheumatoid Arthritis.

Risk Factors

The company faces significant clinical development risk, as its lead program has not yet completed pivotal trials.
As a pre-revenue private company, it is dependent on raising capital to fund expensive late-stage clinical trials and operations.
Competition in both autoimmune and senolytic therapeutic spaces is intense.

Competitive Landscape

Restem competes in the crowded autoimmune therapeutics space against large pharma biologics and a growing number of cell therapy companies. Its differentiation lies in its specific UMPC cell type and off-the-shelf model. In senolytics, it faces competition from both small molecule senolytics and other cell-based approaches targeting aging.

More companies in Cell & Gene Therapy →More companies in United States →